In 2017, a piece of artificial intelligence developed out of UCLA research needed a new home. ONSET Ventures had financed the company behind it, NetSeer. The technology still interested ONSET founder Terry Opdendyk. But according to Inuvo chief executive Richard Howe’s later account, the investing fund was approaching its end, and the decision had been made to stop putting money into the business.
A promising invention and a willing investor might seem like enough. Here was a third variable: the calendar. Inuvo bought substantially all of NetSeer’s assets in exchange for about 3.53 million shares and assumed specified liabilities. The invention could keep going. Its original financing arrangement would not.
- ONSET backs information technology and medical technology businesses.
- Its stated method combines investment with work on the business itself.
- Its portfolio illustrates a founder’s awkward truth: useful technology and a successful investment are different achievements.
The company before the company
Founded in 1984, ONSET belongs to the early-stage venture capital market: the part concerned with turning uncertain beginnings into investable businesses. Its service is capital and judgment. Entrepreneurs receive funding and help; limited partners supply the money that the venture funds put to work.
The distinction matters when looking at its portfolio. ONSET does not sell the planning software developed by Adaptive Insights or the medical devices developed by Relievant. It buys stakes in companies trying to make those products commercially useful. The firm’s fortunes depend on what happens to those stakes.
Opdendyk came to investing through operations. His Berkeley Haas biography lists work at Hewlett-Packard, then Intel, then a four-year stretch as president and chief operating officer of VisiCorp. Running technology businesses preceded financing them. Haas also lists his affiliation with the school from 2003 and his teaching in venture capital and private equity.
There is a clue to ONSET’s market position in that résumé. A founder with a finished business model can shop for money. A founder still working out what the business should become has a different shopping list. Experience with product decisions, hiring and subsequent financing can matter alongside the amount on the check.
A workshop with a checkbook
ONSET called its method “venture craftsmanship.” In a 2007 announcement, it described collaboration that could start before financing closed and continue through a venture’s life. The emphasis was operational and financial milestones. That puts the investor close to decisions that a more distant shareholder might encounter only in a board presentation.
The same announcement brought Diamondhead Ventures founders Raman Khanna and David Lane into ONSET V, a $200 million fund. They continued overseeing Diamondhead’s fund. University and industry relationships were central to the arrangement: people who could identify research, recognize a potential application and help assemble a company around it.
That is a useful distinction from choosing an investor solely for the size of its fund or the familiarity of its name. The relevant question becomes whether the people around the table understand the uncertainty in front of this particular company. Operational involvement has value when it improves a decision. Its mere presence proves little.
The expensive part is finding out
Consider Relievant. In March 2012, ONSET joined a $30 million Series D led by NEA, alongside Canaan Partners, Emergent Medical Partners and Morgenthaler Ventures. The money was intended to advance clinical development, including a randomized trial of its Intracept system. This was a syndicate’s financing, rather than a $30 million check from ONSET alone.
The round bought the opportunity to produce evidence. A medical device can have an appealing mechanism and still need rigorous testing before it becomes a viable commercial proposition. Relievant’s financing makes the milestones unusually tangible: studies, clinical results and the work required to establish a treatment.
Boston Scientific announced a deal for Relievant in September 2023 with $850 million in upfront cash and additional payments tied to sales performance. It completed the acquisition that November. More than eleven years separated the 2012 round and the sale. For this kind of company, patience has a budget.
Three exits, three different stories
Adaptive Insights supplied a larger headline. Workday completed its acquisition in August 2018 for approximately $1.55 billion in aggregate consideration. Opdendyk’s public biography includes Adaptive among the companies he helped guide. An enterprise planning business had become valuable enough for a public software company to buy.
Approximate acquisition consideration paid by Workday. A company transaction value, not ONSET’s proceeds.
Nok Nok Labs offers another scale. The historical ONSET investment developed passwordless authentication software using FIDO standards. OneSpan acquired it in June 2025; later filings report total purchase consideration of $19.2 million. Both transactions are acquisitions. The word alone tells a reader remarkably little about their economics.
NetSeer adds the missing complication. Howe said the company had spread its effort into related software instead of concentrating on the AI capability Inuvo valued. That is the buyer’s assessment, rather than a neutral verdict on every decision NetSeer made. His explanation nevertheless identifies a specific problem: attention had dispersed before the core technology’s commercial potential was fully realized.
The asset sale changed who could develop that technology. It did not establish that ONSET earned an attractive return. Ownership percentages, dilution, security terms and investment costs determine that calculation. A purchase announcement cannot do the arithmetic for us.
Borrow the question
In an interview recorded in December 2014, ONSET partner Shomit Ghose urged founders toward customer value and repeatable sales rather than spectacular-exit fantasies. It is advice that travels beyond venture-backed companies.
“a business that is valued by customers”Shomit Ghose · interview recorded December 2014
The practical adaptation is straightforward: name the uncertainty your next spending decision will resolve. Define the evidence you would accept. Decide beforehand what would make you change direction. This is an interpretation of ONSET’s milestone approach, and a founder can use it without raising a fund-sized dollar.
It requires room to experiment and enough time to act on the result. When clinical evidence takes years, or a fund is nearing closure, good judgment cannot manufacture more calendar. ONSET’s history leaves a useful question on the table: what, exactly, will the next check let you learn?